CoChat

Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanoma

Open access
Veatch, Joshua R., Lee, Sylvia M., Fitzgibbon, Matthew, Chow, I-Ting, Jesernig, Brenda, Schmitt, Tom, Kong, Ying Ying, Kargl, Julia, Houghton, A. McGarry, Thompson, John A., McIntosh, Martin, Kwok, William W., Riddell, Stanley R. · 2018 · Journal of Clinical Investigation
Cited by 125

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

T cells specific for neoantigens encoded by mutated genes in cancers are increasingly recognized as mediators of tumor destruction after immune checkpoint inhibitor therapy or adoptive cell transfer. Unfortunately, most neoantigens result from random mutations and are patient specific, and some cancers contain few mutations to serve as potential antigens. We describe a patient with stage IV acral melanoma who achieved a complete response following adoptive transfer of tumor-infiltrating lymphocytes (TILs). Tumor exome sequencing surprisingly revealed fewer than 30 nonsynonymous somatic mutations, including oncogenic BRAFV600E. Analysis of the specificity of TILs identified rare CD4+ T cells specific for BRAFV600E and diverse CD8+ T cells reactive to nonmutated self-antigens. These specificities increased in blood after TIL transfer and persisted long-term, suggesting they contributed to the effective antitumor immune response. Gene transfer of the BRAFV600E-specific T cell receptor (TCR) conferred recognition of class II MHC-positive cells expressing the BRAF mutation. Therapy with TCR-engineered BRAFV600E-specific CD4+ T cells may have direct antitumor effects and augment CD8+ T cell responses to self- and/or mutated tumor antigens in patients with BRAF-mutated cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci98689

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 125

Metadata

Authors
Veatch, J. R., Lee, S. M., Fitzgibbon, M., Chow, I.-T., Jesernig, B., Schmitt, T., Kong, Y. Y., Kargl, J., Houghton, A. M., Thompson, J. A., McIntosh, M., Kwok, W. W., & Riddell, S. R.
Venue
Journal of Clinical Investigation
Published
2018-03-12
Volume
128
Issue
4
Pages
1563-1568
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W2784995911
Cited by
125
References
13
FWCI
4.89
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanoma. https://app.cochat.ai/papers/10.1172/jci98689
The paper
Veatch, J. R., Lee, S. M., Fitzgibbon, M., Chow, I.-T., Jesernig, B., Schmitt, T., Kong, Y. Y., Kargl, J., Houghton, A. M., Thompson, J. A., McIntosh, M., Kwok, W. W., & Riddell, S. R. (2018). Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanoma. Journal of Clinical Investigation. https://doi.org/10.1172/jci98689

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.